10 stories mentioning SGX:J36Updated just now
Every FINWIRES story that references SGX:J36, newest first.
Jardine Matheson (SGX:J36) unveiled a new $500 million share buyback program, slated for conclusion by the end of 2027, according to a Tuesday filing with the Singapore Exchange.The buyback is part of the company's broader strategy to increase shareholder return and growing its dividend by at least 5% per year.Shares of the conglomerate were down over 4% in Tuesday trading.
Jardine Matheson (SGX:J36) is looking to secure a five-year loan of about AU$1.5 billion to finance the takeover of I-Med Radiology Network, an Australian medical diagnostic imaging provider, Bloomberg News reported on Wednesday, citing people familiar with the matter.The loan could carry an interest margin of around a 100 basis points range over the benchmark Bank Bill Swap Yield, the people told the news outlet. However, the loan discussions are still in the early stages and details could still change, according to the people.A Jardine representative declined to comment, Bloomberg said.The Singapore-listed conglomerate agreed to acquire I-Med for AU$3.4 billion from private equity firm Permira. Under the deal, Jardine will also acquire a minority stake in radiology AI solutions firm, Harrison.ai, the report added.I-Med owns more than 250 clinics across Australia and was acquired by Permira from EQT AB for around $1.3 billion in 2018, the report noted.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Jardine Matheson (SGX:J36) is considering disposing of further assets as part of the conglomerate's strategy to focus on higher growth areas, according to a report by Bloomberg on Friday, citing people familiar with the matter.One of the options on the table is the sale of an office tower in Hong Kong, after initially selling 13 floors to Alibaba Group (HKG:9988) and Ant Group in 2025 for HK$7.2 billion, the report said.The company is also considering selling Hong Kong and Macau-based Mercedes-Benz dealership, Zung Fu, the report added.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Jardine Matheson Holdings' (SGX:J36) purchase of Australia-based I-Med Radiology Network improves its business portfolio, S&P Global Ratings said in a Thursday release.S&P expects the Hong Kong-based conglomerate to boost the acquired firm's growth, given its push for expansion spending and efforts to navigate new markets.I-Med will yield an annual EBITDA growth of between 10% and 15% in its share of Jardine's portfolio, parallel to its 12% reported EBITDA growth over the five years to end-June 2025, S&P said.Organic growth amid a rise in the Australia and New Zealand medical imaging markets, network expansion in these markets, and progress in technology and AI tools will serve as growth drivers, S&P said.Jardine's debt-to-EBITDA ratio should remain under 2x after the acquisition's completion amid organic growth and likely asset sales, S&P said.
Jardine Matheson (SGX:J36) has agreed to fully acquire Australia-based I-Med Radiology Network for AU$3.4 billion as part of its strategy to invest in and control "high-quality businesses" in Asia Pacific.I-Med operates 215 diagnostic imaging clinics across Australia and New Zealand, according to a Monday filing with the Singapore Exchange.The Singapore-listed conglomerate will acquire the business from funds advised by private equity firm Permira.The transaction also includes I-Med's minority stake in Harrison.ai, a developer of AI radiology products.Jardines said the investment is also in line with its plans to expand into "strong growth verticals" such as healthcare diagnostics."As a long-term, committed investor, our goal is to build larger, high-quality businesses across our portfolio, and we look forward to supporting I-MED in the next phase of its growth. I-MED is already a market leader in radiology today, and we expect the business will expand further in I-MED's core markets as well asnew markets," said Jardines CEO Lincoln Pan.I-Med performs more than 7 million patient procedures annually. The imaging services provider has integrated AI medical technologies into its operations alongside its teleradiology system, which allows for the remote interpretation of medical images."We are looking forward to working with Jardines, well known as a long-term investor and owner in the region, to execute on our growth agenda," I-Med CEO Shrey Viranna said."This means continuing to deliver high-quality, expert diagnostic services for the benefit of patients while also enhancing our service offering, implementing AI solutions and exploring international growth opportunities."Jardines, an Asia-focused diversified investment company, has recently ramped up efforts to boost shareholder returns. In November 2025, the conglomerate launched a share buyback program expected to return approximately $250 million to its investors.This followed an October 2025 move to acquire the remaining outstanding shares of Mandarin Oriental International (SGX:M04), subsequently delisting the hotel group from the Singapore bourse.After facing headwinds from U.S. tariff hikes the previous year, Jardines rebounded to profitability for the full year 2025. The company posted a profit attributable to shareholders of $1.11 billion, a sharp recovery from the $468 million loss reported a year earlier.The I-Med acquisition is subject to customary closing conditions, including regulatory approvals, and is expected to be completed later this year, Jardines said.
Jardine Matheson (SGX:J36) agreed to fully acquire Australia-based I-Med Radiology Network from funds advised by Permira for AU$3.4 billion, according to a Monday filing with the Singapore Exchange.The acquisition includes I-Med's minority stake in Harrison.ai, which develops AI radiology products.I-Med operates 215 diagnostic imaging clinics across Australia and New Zealand and performs over 7 million procedures annually.The investment is part of the company's strategy to focus on high-quality businesses across the Asia-Pacific region, Jardine Matheson said.Shares of the Singapore-listed conglomerate rose nearly 2% in recent trade.
Jardine Matheson (SGX:J36) bought back 15,200 shares in the open market on Monday for a weighted average price of $68.65 apiece, according to a Tuesday filing with the Singapore Exchange.The repurchased shares will be canceled.
Jardine Matheson (SGX:J36) declared a final dividend of $1.75 per share for 2025, according to a Wednesday filing with the Singapore Exchange.The dividend will be paid on May 13, the filing added.
Jardine Matheson (SGX:J36) bought back 15,000 shares in the open market on Tuesday for $72.3469 per share, according to a same-day filing with the Singapore Exchange.The repurchased shares will be canceled.
Jardine Matheson (SGX:J36) bought back 15,000 shares in the open market on Monday for $73.2874 per share, according to a Wednesday filing with the Singapore Exchange.The repurchased shares will be canceled.
